Business News / Stocks

ImmunoGen Reports Positive Findings

ImmunoGen (IMGN) on Wednesday reported positive data from its FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in patients with folate receptor alpha-positive ovarian cancer.

The drugmaker said results from the cohort assessing mirvetuximab in combination with Avastin in patients with platinum-resistant disease will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 1-5 in Chicago, IL.

The firm said it would also give updated data from the dose-escalation cohort evaluating mirvetuximab in combination with carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

“The promising new data…support the potential of mirvetuximab combinations in earlier lines of therapy,” said Anna Berkenblit,Chief Medical Officer of ImmunoGen. “Together, these results have informed the triplet combination study with mirvetuximab plus carboplatin and Avastin, which we initiated last quarter.”